Morgan Stanley assumed coverage of Certara (CERT) with an Equal Weight rating and $16 price target The firm says it awaits further potential updates on Certara’s strategic review of the regulatory services business and management commentary regarding the near- or mid-term impact that may result from Certara’s opportunity set coming from the FDA’s previous announcement to gradually reduce animal testing in favor of new approach methodologies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT:
- Certara’s Steady Growth Amid Strategic and Regulatory Uncertainties: A Hold Rating Analysis
- Schrodinger appoints Mannix Aklian as chief commercial officer
- Certara Holds Annual Stockholders Meeting on May 21
- Certara’s Stable Outlook: Hold Rating Maintained Amid Strategic and Financial Consistency
- Certara upgraded to Overweight from Equal Weight at Barclays